Eptifab 0.75mg/ml Infusion
Marketer
Abbott
Salt Composition
Eptifibatide (0.75mg/ml)
Overview Eptifab 0.75mg/ml Infusion
Eptifab 0.75mg/ml infusion is an anticoagulant preventing the development of dangerous blood clots. It treats heart attacks and inhibits clot formation during angioplasty (a procedure restoring heart blood flow). Administration requires strict physician oversight; dosage and treatment length are determined individually. Concurrently prescribed medications should be continued as directed. Thrombocytopenia (low platelet count) and increased bleeding risk are potential side effects. Report immediate signs like petechiae (pinpoint rash) or blood in excretions to your doctor. Hypotension (low blood pressure) is another possible adverse reaction. Your doctor will discuss the treatment's benefits and potential risks prior to administration. Caution is advised for patients with bleeding disorders, hepatic or renal impairment. Pregnant or breastfeeding patients, and those taking other medications, must inform their physician before treatment.
Primary Ingredients of Eptifab 0.75mg/ml Infusion
No text provided. Please provide the text you wish to be rephrased.
Uses of Eptifab 0.75mg/ml Infusion
Thrombosis prophylaxis | Myocardial infarction prevention
Major Benefits of Eptifab 0.75mg/ml Infusion:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Eptifab 0.75mg/ml Infusion:
- Bleeding
- Decreased blood pressure
How to use Eptifab 0.75mg/ml Infusion:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Eptifab 0.75mg/ml Infusion works:
Eptifibatide 0.75mg/ml infusion solution acts as an antithrombotic agent, inhibiting platelet aggregation and thus reducing the risk of dangerous thrombus development.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Eptifab 0.75mg/ml Infusion is unstudied regarding safety. Seek medical advice before combining them.
PregnancySAFE IF PRESCRIBED
The intravenous administration of Eptifab at a concentration of 0.75mg/ml is typically deemed safe for pregnant individuals. Preclinical trials using animals revealed minimal or no negative consequences for fetal development; nevertheless, data from human clinical trials remain scarce.
Breast feedingCAUTION
Administering Eptifab 0.75mg/ml Infusion to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment and until the medication is fully cleared from her system.
DrivingNOT RELEVANT
Eptifab 0.75mg/ml Infusion is administered solely within a hospital setting.
KidneyCAUTION
Patients with impaired kidney function require careful monitoring when receiving Eptifab 0.75mg/ml Infusion, potentially necessitating dose modification. Physician consultation is advised. Eptifab 0.75mg/ml Infusion is contraindicated in individuals with severely compromised renal function.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Eptifab 0.75mg/ml Infusion to individuals with hepatic impairment. Physician consultation is advised. Eptifab 0.75mg/ml Infusion is contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Eptifab 0.75mg/ml Infusion :
Omit a dose of Eptifab 0.75mg/ml Infusion? Seek medical advice immediately.
Facts to Know About Eptifab 0.75mg/ml Infusion
| Label | Value |
|---|---|
| Chemical Category | Amino acid and peptide analogs |
| Developing Habits | No. |
| Treatment Category | KINSHIP |
| Actions | IIb/IIIa receptor antagonists |
3,018 People bought this recently